Auris tries to rebound from PhIII failure with new trial design; Kymab ties the knot with Shanghai-based EpimAb

Two months after its shares were crushed in a rout following the failure of a key late-stage study of its tinnitus treatment, Auris Medical $EARS is asking to change up the ongoing Phase III followup trial in an attempt to salvage a victory out of the effort. Working off the first round of data, Auris wants to elevate the change in Tinnitus Functional Index (TFI) scores from a key secondary endpoint to an alternate primary efficacy endpoint. The biotech says it’s prepared to expand the study to make the change work for regulators.

In a marriage of platform technologies, the UK’s Kymab is set to go to work with Shanghai-based EpimAb Biotherapeutics’ bispecific antibodies as well as antibodies developed with its Kymouse platform to develop new immuno-oncology therapies. Kymab gets to keep ex-China rights with EpimAb hanging on to the Asian country rights.

Lexington, MA-based Curis is in-licensing a PD-1/ TIM-3 antagonist program from Aurigene dubbed CA-327.

Paratek Pharmaceuticals $PRTK has entered into a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases of public health and biodefense importance.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->